<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Geron Corp. | Company News & Executive Profiles - GERN | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/geron+corp..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Geron Corp.]]></description>
	<s:counts start="0" returned="10" found="37" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Geron: Huge Potential in Oncology, Regenerative Med Pipeline]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F156858-geron-huge-potential-in-oncology-regenerative-med-pipeline%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[VFC submits:  Shares of Geron Corporation GERN traded down 10% during early trading on Tuesday due to a report that the FDA placed a clinical hold on the company's investigational new drug application for a cell therapy that treats spinal cord injuries. The FDA, according to the report, placed...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 18 Aug 2009 11:53:08 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/vfc%2527s+stock+house.html"><![CDATA[VFC's Stock House]]></category>
		<category domain="http://resources.bnet.com/topic/geron+corp..html"><![CDATA[Geron Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GERN</category>
		<category domain="tickers">GERN</category>
	</item>
	<item>
		<title><![CDATA[Geron Pushes Higher on GE Healthcare Alliance]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F146343-geron-pushes-higher-on-ge-healthcare-alliance%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Jamie Moye submits: Geron Corp. GERN yesterday traded strongly higher after announcing a collaboration with GE Healthcare to develop and commercialize evaluation technologies from human embryonic stem cells hESCs.  The multi-year collaboration is designed to assist in the discovery of new drugs, their ongoing development and toxicity screening. ...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 01 Jul 2009 12:53:09 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/beacon+asset+managers.html"><![CDATA[Beacon Asset Managers]]></category>
		<category domain="http://resources.bnet.com/topic/general+electric+co..html"><![CDATA[General Electric Co.]]></category>
		<category domain="http://resources.bnet.com/topic/geron+corp..html"><![CDATA[Geron Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GE</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GERN</category>
		<category domain="tickers">GE,GERN</category>
	</item>
	<item>
		<title><![CDATA[Geron's Risk-Reward Profile - Best in Biotech?]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F142880-geron-s-risk-reward-profile-best-in-biotech%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Jamie Moye submits: By Jamie Moye   Within the next three months, certainly before the end of August, some poor soul is going to find himself in the hospital with a broken back, facing a future life as a paraplegic.  With essentially no hope of a cure from...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Fri, 12 Jun 2009 04:30:44 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/beacon+asset+managers.html"><![CDATA[Beacon Asset Managers]]></category>
		<category domain="http://resources.bnet.com/topic/geron+corp..html"><![CDATA[Geron Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GERN</category>
		<category domain="tickers">GERN</category>
	</item>
	<item>
		<title><![CDATA[Geron: Strong Investment in Human Embryonic Stem Cell Research]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F139397-geron-strong-investment-in-human-embryonic-stem-cell-research%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Let me get the disclaimer out of the way first. I am not a medical doctor or biologist. I feel too many economists and analysts who do not have a background in these areas pretend that they do and write as such, but really have no clue what they are...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 25 May 2009 01:01:47 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/ryan+pollack.html"><![CDATA[Ryan Pollack]]></category>
		<category domain="http://resources.bnet.com/topic/geron+corp..html"><![CDATA[Geron Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GERN</category>
		<category domain="tickers">GERN</category>
	</item>
	<item>
		<title><![CDATA[Geron: The Excitement is Back]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F125252-geron-the-excitement-is-back%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Investment U submits:  By Katharine Schildt A simple signature from a government official created at least $50 million in wealth Monday. It&#8217;s about time&#8230; because it seems as though government officials had been doing nothing but destroying wealth lately. by Investment U]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 10 Mar 2009 11:55:38 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/investment+u.html"><![CDATA[Investment U]]></category>
		<category domain="http://resources.bnet.com/topic/geron+corp..html"><![CDATA[Geron Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GERN</category>
		<category domain="tickers">GERN</category>
	</item>
	<item>
		<title><![CDATA[Geron Opens a New Era for Stem Cell Research]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F116754-geron-opens-a-new-era-for-stem-cell-research%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Investment U submits:  Stem cell research has been a controversial subject for quite some time. And it&#8217;s been no secret that the Bush administration wasn&#8217;t a big fan. But just days after President Obama&#8217;s inauguration, a huge breakthrough has already been made in the administrative logjam. Obama officially relaxed...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 27 Jan 2009 07:22:34 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/investment+u.html"><![CDATA[Investment U]]></category>
		<category domain="http://resources.bnet.com/topic/geron+corp..html"><![CDATA[Geron Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GERN</category>
		<category domain="tickers">GERN</category>
	</item>
	<item>
		<title><![CDATA[Geron Corp: Up 50% on Nothing but Hope]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F116708-geron-corp-up-50-on-nothing-but-hope%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Eric Falkenstein submits:  The WSJ noted: Geron Corp., a Menlo Park, Calif., biotechnology company, is expected to announce Friday that it received a green light from the agency to mount a study of its stem-cell treatment for spinal cord injuries in up to 10 patients. by Eric Falkenstein]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 27 Jan 2009 04:59:24 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/eric+falkenstein.html"><![CDATA[Eric Falkenstein]]></category>
		<category domain="http://resources.bnet.com/topic/geron+corp..html"><![CDATA[Geron Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GERN</category>
		<category domain="tickers">GERN</category>
	</item>
	<item>
		<title><![CDATA[Was Geron's Announcement Timed?]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F116288-was-geron-s-announcement-timed%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mike Huckman submits:  A few days into his term, President Obama appears to have begun to undo another Bush-era policy. He hasn't yet formally lifted the Bush-imposed ban on federal funding of new embryonic stem cell research, but Obama's Food and Drug Administration has already set the stage for...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Sun, 25 Jan 2009 01:45:49 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/mike+huckman.html"><![CDATA[Mike Huckman]]></category>
		<category domain="http://resources.bnet.com/topic/geron+corp..html"><![CDATA[Geron Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GERN</category>
		<category domain="tickers">GERN</category>
	</item>
	<item>
		<title><![CDATA[Geron Presentations at the ASCO 2008 Annual Meeting]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_June_2/ai_n25470921]]></link>
		<description><![CDATA[New Data on Activity of GRN163L in T-cell Prolymphocytic Leukemia Cells  MENLO PARK, Calif. -- Geron Corporation (Nasdaq:GERN) today announced two presentations of its anti-cancer drug, GRN163L, given at the American Society of Clinical Oncology ASCO annual meeting in Chicago.  Geron is currently testing GRN163L in four clinical...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 02 Jun 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/asco+plc..html"><![CDATA[Asco Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/geron+corp..html"><![CDATA[Geron Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GERN</category>
		<category domain="tickers">GERN</category>
	</item>
	<item>
		<title><![CDATA[Geron Corporation Q1 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-226334.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions. Your first question comes from the line of [Glen Gechlik] with Needham & Co. Please proceed. Glen Gechlik- Needham & Co. [Technical Difficulty] any further follow-up on the stem cell program and when the IND might be expected. Tom Okarma Well fair question. But again,...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Fri, 30 May 2008 07:45:22 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/geron+corp..html"><![CDATA[Geron Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GERN</category>
		<category domain="tickers">GERN</category>
	</item>
</channel>
</rss>
